ArticleAmerican journal of ophthalmology case reports2022
Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab.
Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Iris metastasis from lung adenocarcinoma diagnosed solely through aqueous humor cytology: A case report.American journal of ophthalmology case reports · 2026Article
- Impact of Chemotherapy and Radiotherapy on Iris Metastases: A Case Report.Ocular oncology and pathology · 2026Article
- Are iris masses in lung carcinoma always a metastasis: Two case reports.World journal of methodology · 2026Article
- A case of masquerade syndrome caused by metastatic iris tumor diagnosed by a high CEA level in the aqueous humor and iris biopsy.Diagnostic pathology · 2024Article
- [Clinical approach for solid intraocular metastases].Die Ophthalmologie · 2024Review
- Rapid progress of an iris metastasis from esophageal cancer: a case report and review of literature.International journal of ophthalmology · 2024Review
- Undetected Ocular Mass as a Critical Alert for Identifying Uveal Metastasis.Case reports in ophthalmological medicine · 2024Article
- Inhibition of vascular endothelial growth factor-A downregulates angiogenesis in psoriasis: A pilot study.Skin health and disease · 2023Article
- Salivary Exosomes in Health and Disease: Future Prospects in the Eye.International journal of molecular sciences · 2023Review
- A Case of Metastatic Iris Tumor from Adenocarcinoma of the Cecum Diagnosed by Combined Tumor Markers in Aqueous Humor and Fine Needle Aspiration Cytology.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIris metastases from lung cancer occur rarely. Current treatment options such as surgical iridectomy or radiotherapy are invasive and can potentially lead to negative side effects. Other less invasive alternatives include chemotherapy and intracameral bevacizumab. OBSERVATIONS: An 81 year-old female with metastatic non-small cell lung adenocarcinoma to the iris in the right eye was treated with daily oral osimertinib 80mg, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), for her systemic lung cancer. In addition, 8 monthly intravitreal bevacizumab (1.25mg/0.05 cc) injections were given. The iris tumor demonstrated complete regression by the third cycle of osimertinib. Following 21 months of osimertinib and 8 bevacizumab injections, the tumor remained regressed. Subsequent iris biopsy confirmed complete tumor regression. CONCLUSIONS AND IMPORTANCE: In this case, osimertinib and monthly intravitreal bevacizumab controlled iris metastasis due to non-small cell lung cancer. Osimertinib can be beneficial for patients with EGFR-positive lung cancer for both ocular and systemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.